Human Molecular Genetics Advance Access originally published online on September 14, 2005
Human Molecular Genetics 2005 14(21):3169-3178; doi:10.1093/hmg/ddi344
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations
1Department of Internal Medicine, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi, 27100 Pavia, Italy, 2Centre of Excellence for Applied Biology, University of Pavia, via Bassi, 27100 Pavia, Italy, 3Division of Hematology, IRCCS Policlinico San Matteo, Piazzale Golgi, 27100 Pavia, Italy and 4Telethon Institute of Genetics and Medicine (TIGEM), via Castellino, 80131 Napoli, Italy
* To whom correspondence should be addressed. Tel: +39 382501358; Fax: +39 382526223; Email: alessandro.pecci{at}unipv.it
Received July 12, 2005; Accepted September 9, 2005
Mutations of MYH9, the gene for non-muscle myosin heavy chain IIA (NMMHC-IIA), cause a complex clinical phenotype characterized by macrothrombocytopenia and granulocyte inclusion bodies, often associated with deafness, cataracts and/or glomerulonephritis. The pathogenetic mechanisms of these defects are either completely unknown or controversial. In particular, it is a matter of debate whether haploinsufficiency or a dominant-negative effect of mutant allele is responsible for hematological abnormalities. We investigated 11 patients from six pedigrees with different MYH9 mutations. We evaluated NMMHC-IIA levels in platelets and granulocytes isolated from peripheral blood and in megakaryocytes (Mks) cultured from circulating progenitors. NMMHC-IIA distribution in Mks and granulocytes was also assessed. We demonstrated that all the investigated patients had a 50% reduction of NMMHC-IIA expression in platelets and that a similar defect was present also in Mks. In subjects with R1933X and E1945X mutations, the whole NMMHC-IIA of platelets and Mks was wild-type. No NMMHC-IIA inclusions were observed at any time of Mk maturation. In granulocytes, the extent of NMMHC-IIA reduction in patients with respect to control cells was significantly greater than that measured in platelets and Mks, and we found that wild-type protein was sequestered within most of the NMMHC-IIA inclusions. Altogether these results indicate that haploinsufficiency of NMMHC-IIA in megakaryocytic lineage is the mechanism of macrothrombocytopenia consequent to MYH9 mutations, whereas in granulocytes a dominant-negative effect of mutant allele is involved in the formation of inclusion bodies. The finding that the same mutations act through different mechanisms in different cells is surprising and requires further investigation.
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kunishima, M. Hamaguchi, and H. Saito Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders Blood, March 15, 2008; 111(6): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Franke, R. A. Montague, W. L. Rickoll, and D. P. Kiehart An MYH9 human disease model in flies: site-directed mutagenesis of the Drosophila non-muscle myosin II results in hypomorphic alleles with dominant character Hum. Mol. Genet., December 15, 2007; 16(24): 3160 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Martinelli, M. Di Stazio, L. Scapoli, J. Marchesini, F. Di Bari, F. Pezzetti, F. Carinci, A. Palmieri, P. Carinci, and A. Savoia Cleft lip with or without cleft palate: implication of the heavy chain of non-muscle myosin IIA J. Med. Genet., June 1, 2007; 44(6): 387 - 392. [Abstract] [Full Text] [PDF]
|
|